Boehringer stops tipranavir trial in treatment-naïve patients

HIV Treat Bull - Vol. 7, No. 7/8, July/August 2006

On 13 June 2006, Boehringer Ingelheim announced that it was closing a clinical trial of HIV drug tipranavir (Aptivus) in treatment-naïve patients due to insufficient effectiveness at 60 weeks.

Tipranavir was approved in Europe in October 2005 and is currently only indicated in combination with ritonavir in treatment-experienced patients who are resistant to other PIs.

The study that has now been closed, BI 1182.33, recruited 558 treatment-naïve patients in 15 countries including France, Germany and the UK, and was a non-inferiority trial against lopinavir/r (Kaletra), whose primary endpoint was the proportion of patients with an undetectable viral load (< 50 copies/mL).

Patients in both tipranavir arms received 500 mg tipranavir twice daily. Only the ritonavir dose varied, at 200 mg or 100 mg twice daily.

For both doses of ritonavir, tipranavir’s non-inferiority was proved at 48 weeks.

However, following this, the 200 mg ritonavir arm was closed due to an asymptomatic elevation of liver enzyme levels. This phenomenon had already been observed in the RESIST treatment-experienced trials.

A subsequent 60-week analysis, showed that the effect of tipranavir/ritonavir (500 mg/100 mg twice daily) had declined and that this therapy was now inferior to Kaletra in terms of virologic success.

The press release does not specify the proportion of patients with undetectable viral loads, but says that there was a 15.03% difference between the lopinavir/r and tipranavir arms, 0.3% above the limit fixed in the trial protocol.

Boehringer Ingelheim decided at this point to halt the whole trial, specifying that this “does not change the positive benefit-risk profile of tipranavir/ritonavir (500 mg/200 mg) for the highly treatment-experienced patient population for which it is currently indicated.”

Source:

Boehringer Ingelheim Press Release (13 June 2006)

2008-03-10
IB060707-19

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.